article

Expert view: Finding a translatable disease model suitable for drug discovery screening

Posted: 28 May 2020 | | No comments yet

Effective drug discovery and development greatly relies on the availability of predictive pre-clinical models.

For decades, target-based drug discovery has focused on biochemical assays or selected protein over-expression in immortalised cells to identify and optimise inhibitory or activating molecules. Only late during the drug development pipeline are molecules tested on more complex biological systems – typically in animals. However, animal experiments are costly and findings can translate poorly to humans.











To read this expert view in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsor: Ncardia

Related organisations

Send this to a friend